Research

EMBL researchers showed for the first time that adding a sugar to proteins inside cells is crucial for embryo development and for shutting down completely harmful parts of the genome in vivo Protein modifications are key to cell survival because they ensure they do what they are supposed to do in a healthy system. One […]

Ladenburg, Germany, 13 January 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that it is advancing into Cohort 7 in a Phase I/IIa dose escalation study with lead ATAC candidate HDP-101 for the treatment of relapsed or refractory multiple myeloma. Previously, in Cohort 6, dose […]

Non-viral platform for efficient drug transfer to facilitate clinical developments Heidelberg, 15.01.2025 – PROGEN, leading manufacturer of Adeno-Associated-Virus (AAV) analytical tools for gene therapy research and development, announces the launch of LNPs for the versatile delivery of therapeutic agents into cells. In the past decade, PROGEN has driven progress in gene therapy by providing reliable […]

EMBL and ELLIS deepen relationship to drive artificial intelligence (AI) in European life science research, training, and technology A new collaborative agreement aims to help position Europe at the forefront of AI-driven advancements in life sciences research. The European Molecular Biology Laboratory (EMBL) and the European Laboratory for Learning and Intelligent Systems (ELLIS) have agreed […]

Study identifies a novel mechanism driving osteosarcoma and provides insights to help predict patient outcomes Summary Osteosarcoma is a type of aggressive bone cancer that most commonly affects children and young adults between the ages of 10 and 20, during times of rapid bone growth. Although rare, it has a significant impact on young people […]

If the development of blood vessels in the placenta is impaired, fetal growth retardation may result. Scientists from the German Cancer Research Center (DKFZ) and the Mannheim Medical Faculty of Heidelberg University discovered that the correct development of functioning blood vessels in the mouse placenta is controlled epigenetically: One of the enzymes that modify gene […]

Alcedis is a globally operating, leading full-service CRO with over 30 years of experience in clinical research. As a member of the Huma Group, they combine deep expertise with innovative AI-driven technologies to conduct clinical trials efficiently and accurately – from Phase I to market authorization, medical device projects, and real-world evidence. Their in-house competence […]

The curATime cluster is one of 14 pioneering “Clusters4Future” initiatives funded by the German Federal Ministry of Education and Research (BMBF). Its mission is to promote personalized approaches to combat atherothrombosis-related diseases and to establish the Rhine-Main-Palatinate region as an international driver of innovation. For the planned second implementation phase, the cluster is seeking new […]

Tumor cells circulating in the blood are the “germ cells” of breast cancer metastases. They are very rare and could not be propagated in the culture dish until now, which made research into therapy resistance difficult. A team from the German Cancer Research Center (DKFZ), the Heidelberg Stem Cell Institute HI-STEM* and the NCT Heidelberg** […]